Immunic’s (IMUX) Buy Rating Reiterated at D. Boral Capital

Immunic (NASDAQ:IMUX)‘s stock had its “buy” rating reissued by analysts at D. Boral Capital in a report released on Wednesday,Benzinga reports. They currently have a $10.00 price objective on the stock.

A number of other brokerages also recently weighed in on IMUX. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Immunic in a report on Thursday, May 1st. Wall Street Zen cut shares of Immunic from a “hold” rating to a “sell” rating in a research report on Thursday, March 20th. William Blair reiterated an “outperform” rating on shares of Immunic in a research report on Friday, May 16th. Finally, B. Riley reissued a “buy” rating and set a $5.00 price objective (down previously from $6.00) on shares of Immunic in a report on Friday, May 23rd. One analyst has rated the stock with a sell rating, six have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $11.60.

Immunic Price Performance

NASDAQ IMUX opened at $0.71 on Wednesday. Immunic has a 12 month low of $0.56 and a 12 month high of $2.11. The company’s 50 day simple moving average is $0.91 and its 200 day simple moving average is $1.01. The company has a market capitalization of $68.07 million, a P/E ratio of -0.58 and a beta of 1.48.

Immunic (NASDAQ:IMUX) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.25) earnings per share for the quarter, meeting the consensus estimate of ($0.25). On average, analysts anticipate that Immunic will post -0.94 earnings per share for the current year.

Hedge Funds Weigh In On Immunic

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. 683 Capital Management LLC boosted its stake in Immunic by 2.2% in the fourth quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock valued at $700,000 after acquiring an additional 15,349 shares during the last quarter. Bridgeway Capital Management LLC boosted its stake in Immunic by 11.5% in the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock valued at $215,000 after acquiring an additional 22,200 shares during the last quarter. Focus Partners Wealth boosted its stake in Immunic by 1.1% in the fourth quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock valued at $2,168,000 after acquiring an additional 23,610 shares during the last quarter. Invesco Ltd. bought a new position in Immunic in the fourth quarter valued at approximately $37,000. Finally, Barclays PLC bought a new position in Immunic in the fourth quarter valued at approximately $84,000. 51.82% of the stock is owned by institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.